MIT’s new ‘recursive’ framework lets LLMs process 10 million tokens without context rot

While standard models suffer from context rot as data grows, MIT’s new Recursive Language Model (RLM) framework treats ...
The Motley Fool

Down 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip?

Recursion Pharmaceuticals is a TechBio company trying to apply artificial intelligence (AI) to the new drug-discovery process. The first placebo-controlled trial results from Recursion Pharmaceuticals ...
The Motley Fool

Is Recursion Pharmaceuticals Stock a Buy?

Recursion is seeking to revolutionize the way we develop drugs. If it's successful, the biotech will reap immense benefits. However, the stock is somewhat risky for now. The process of developing ...
Seeking Alpha

Recursion Pharmaceuticals: More Of A TechBio Industrializing Drug Discovery

This thesis makes the case for an investment in Recursion Pharmaceuticals operating as a TechBio which "industrializes" the process of drug discovery in contrast to a typical biotech. The difference ...
CNBC

Recursion Pharmaceuticals CEO explains how AI could make drug development faster and less costly

Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...
Business Insider

Recursion Secures $1.6M NIH Phase 2 SBIR Grant to Identify Therapeutic Candidates for Senescence, a Key Age-Related Disease Process

SALT LAKE CITY, Nov. 8, 2018 /PRNewswire/ -- Recursion Pharmaceuticals, a biotechnology company that combines artificial intelligence (AI), experimental biology, and automation to discover and develop ...
Nasdaq

Recursion Pharmaceuticals’ (RXRX) Bold Acquisition Places it as an Industry Leader

Recursion Pharmaceuticals (RXRX), a trailblazer in AI-powered drug discovery, recently acquired its competitor, Exscientia, in a strategic move that solidifies its leading position in the industry.
Seeking Alpha

Recursion Pharmaceuticals: AI-Driven 'TechBio' With Upcoming Catalysts

Recursion Pharmaceuticals uses AI in drug development, increasing success rates in lab and animal testing, with upcoming data readouts for five Phase 2 programs. The company is a "TechBio," with ...